DJIA 16,058.35 -469.68 -2.84%
NASDAQ 4,636.11 -140.40 -2.94%
S&P 500 1,913.85 -58.33 -2.96%
market minute promo

Delcath Systems, Inc. (NASDAQ: DCTH)

0.43 -0.01 (-1.80%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

DCTH $0.43 -1.80%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $0.44
Previous Close $0.44
Daily Range $0.41 - $0.44
52-Week Range $0.36 - $2.78
Market Cap $9.4M
P/E Ratio -0.32
Dividend (Yield) $0.00 (0.0%)
Volume 64,934
Average Daily Volume 428,343
Current FY EPS $0.00

Sector

Healthcare

Industry

Drug Makers

Delcath Systems, Inc. (DCTH) Description

The Company is a development stage Company. Website: http://www.delcath.com/

News & Commentary

Why Did My Stock Just Die?

These stocks just rolled over. Which ones will bounce back?

Five NCAV Companies for Value Investors - August 2015

Delcath Receives Orphan Drug Designation From FDA For Melphalan To Treat Cholangiocarcinoma

Worst Performing Industries For June 2, 2015

Delcath Systems (DCTH) Weak On High Volume

Health Care Sector Update for 05/29/2015: DCTH,KBIO,SVON,XXII

Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015

Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest EPS Growth Forecast For Next 5 Ye

Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest EPS Growth Forecast For Next 5 Years

ICC Cohort Of Delcath's Global Phase 2 Trial Of Melphalan/HDS In Hepatocellular Carcinoma Now Open F

ICC Cohort Of Delcath's Global Phase 2 Trial Of Melphalan/HDS In Hepatocellular Carcinoma Now Open For Enrollment

Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic

Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic Cholangiocarcinoma

3 Basic Checks To Value Cheap Net Net Stocks

See More DCTH News...

DCTH's Top Competitors

DCTH $0.43 (-1.80%)
Current stock: DCTH
$0.00 (0.00%)
Current stock:
MDT $69.53 (-3.82%)
Current stock: MDT
COV $0.00 (0.00%)
Current stock: COV